{"id":10513,"date":"2025-05-30T10:59:00","date_gmt":"2025-05-30T09:59:00","guid":{"rendered":"https:\/\/ep-ad.org\/?p=10513"},"modified":"2025-10-21T11:00:30","modified_gmt":"2025-10-21T10:00:30","slug":"brain-communications","status":"publish","type":"post","link":"https:\/\/ep-ad.org\/index.php\/2025\/05\/30\/brain-communications\/","title":{"rendered":"Brain communications"},"content":{"rendered":"\n

“Brain MRI signatures across sex and CSF Alzheimer\u2019s disease biomarkers”<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Authors:<\/strong> You Cheng, Yingnan He Karthik Gopinath, Benjamin Billot, Juan Eugenio Iglesias, Chao-Yi Wu, Hiroko Dodge, Anne-Marie Will, Becky Carlyle, Pia Kivis\u00e4kk, Bradley T Hyman, Steven E Arnold, Sudeshna Das; for the Alzheimer\u2019s Disease Neuroimaging Initiative and for the European Prevention of Alzheimer\u2019s Disease (EPAD) Consortium<\/p>\n\n\n\n

Abstract:<\/strong><\/p>\n\n\n\n

The relationship between cerebrospinal fluid (CSF) biomarkers of Alzheimer\u2019s disease and neurodegenerative effects is not fully understood. This study investigates neurodegeneration patterns across CSF Alzheimer\u2019s disease biomarker groups, the association of brain volumes with CSF amyloid and tau status and sex differences in these relationships in a clinical neurology sample. MRI and CSF Alzheimer\u2019s disease biomarkers data were analysed in 306 patients of the Mass General Brigham healthcare system aged 50+ (mean age = 68.4 \u00b1 8.8 years; 43.1% female), who had lumbar punctures within 1 year of clinical MRI scans. We first analysed neurodegeneration patterns across four biomarker groups: 60 controls (A\u2212T\u2212&CU; amyloid negative, tau negative, cognitively unimpaired), 25 A+T\u2212 (amyloid positive, tau negative), 121 A+T+ (amyloid positive, tau positive) and 100 other dementia (A\u2212T\u2212&CI; amyloid negative, tau negative, cognitively impaired). Second, we examined volumetric associations with amyloid (amyloid positive, tau negative versus control) and tau in the presence of amyloid (amyloid positive, tau positive versus amyloid positive, tau negative) across 52 brain areas. Third, we examined sex differences in these relationships. Finally, we validated core analyses across three independent datasets\u2014NACC (National Alzheimer\u2019s Coordinating Center), ADNI (Alzheimer\u2019s Disease Neuroimaging Initiative) and EPAD (European Prevention of Alzheimer\u2019s Dementia)\u2014totalling 3137 participants, and performed meta-analyses to obtain more robust estimates. We observed distinct neurodegeneration patterns across biomarker groups, with disrupted connectivity (brain volume covariance networks) in amyloid positive and other dementia groups, while amyloid and tau negative, cognitively unimpaired controls exhibited the most connected network. Amyloid was associated with subcortical, cerebellar and brainstem atrophy, with consistent association observations in the thalamus and amygdala across all four datasets. Tau in the presence of amyloid demonstrated general brain shrinkage through enlargement of extracerebral CSF, alongside unexpected ventricle shrinkages. Sex-based analyses revealed that A+T+ (amyloid positive, tau positive) had lower sex differences in connectivity patterns compared with other groups. Sex differences were also noted in amyloid-related ventricular volume changes. This study reveals how amyloid and tau affect brain connectivity and volume across sex and CSF biomarker groups, emphasizing global brain changes and sex differences. By leveraging automated pipelines and advanced MRI and biomarker analyses, we extracted meaningful and replicable findings from heterogeneous clinical samples from real-world data. The meta-analyses across four datasets enhance the generalizability of our results.<\/p>\n\n\n\n

DOI:<\/strong> <\/a>10.1093\/braincomms\/fcaf210<\/a><\/p>\n\n\n\n

Published online:\u00a030 May 2025 in the journal Brain Communications<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

“Brain MRI signatures across sex and CSF Alzheimer\u2019s disease biomarkers” Authors: You Cheng, Yingnan He Karthik Gopinath, Benjamin Billot, Juan Eugenio Iglesias, Chao-Yi Wu, Hiroko Dodge, Anne-Marie Will, Becky Carlyle, Pia Kivis\u00e4kk, Bradley T Hyman, Steven E Arnold, Sudeshna Das; for the Alzheimer\u2019s Disease Neuroimaging Initiative and for the European Prevention of Alzheimer\u2019s Disease (EPAD) […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[],"class_list":["post-10513","post","type-post","status-publish","format-standard","hentry","category-publications"],"_links":{"self":[{"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/posts\/10513","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/comments?post=10513"}],"version-history":[{"count":1,"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/posts\/10513\/revisions"}],"predecessor-version":[{"id":10515,"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/posts\/10513\/revisions\/10515"}],"wp:attachment":[{"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/media?parent=10513"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/categories?post=10513"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/tags?post=10513"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}